Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024

17 Oct 2022

• By Jessica Merrill

An unblinded interim efficacy analysis by a DMC recommended a Phase II/III study testing fosgonimeton in Alzheimer's patients should continue.

car veering — Athira thinks its Alzheimer's drugs is back on the development road • Source: Shutterstock

More from Clinical Trials

More from R&D